Overview of Immune Checkpoint Inhibitors Therapy for Hepatocellular Carcinoma, and the ITA.LI.CA Cohort Derived Estimate of Amenability Rate to Immune Checkpoint Inhibitors in Clinical Practice
Cancers - Switzerland
doi 10.3390/cancers11111689
Full Text
Open PDFAbstract
Available in full text
Date
October 30, 2019
Authors
Publisher
MDPI AG